Concord Biotech Q2 (consol): PAT +10% YoY trails 25% revenue growth as margins compress

Concord Biotech's consolidated revenue rose 25.1% YoY to ₹309.07 Cr (and 20.0% QoQ from ₹257.49 Cr), while consolidated PAT grew a slower 10.3% YoY to ₹69.57 Cr (+20.6% QoQ from ₹57.70 Cr) — profit growth clearly trailing topline growth on a year-on-year basis, which is the number that matters here over the sharper sequential PAT jump. Both figures land inside the range our pre-result preview flagged (revenue +22-28% YoY, PAT margin 21-23%): actual NPM came in at 21.8%, squarely inline with expectations and with no street preview numbers found for this specific print beyond our own. Against management's FY27 guidance of >25% CAGR growth and a 40%-by-FY28 EBITDA margin path (from 32% at the Q1 call), this quarter's 25.1% YoY growth keeps pace with the growth target, and OPM at 33.87% is a step up from Q1's 31.99%, so the margin trajectory is on track even though it is still running below both the FY28 target and last year's 35.82%. The YoY margin compression (OPM 35.82%→33.87%, NPM 24.22%→21.79%) is the real story behind the print. Employee benefit expense rose 17.7% YoY and power & fuel costs rose 28.4% YoY — consistent with management's own framing of injectable-facility ramp costs and operating leverage building gradually rather than instantly — while other income fell 23.8% YoY to ₹10.17 Cr from ₹13.35 Cr, further pressuring PBT. Sequentially, margins did expand (NPM 21.34%→21.79%, OPM 31.99%→33.87%), so the compression is a YoY phenomenon layered on top of a QoQ improvement, not a deteriorating trend quarter-on-quarter. Standalone tells a materially stronger story: standalone PAT grew 20.4% YoY to ₹75.71 Cr, roughly double the consolidated PAT growth rate — a gap worth flagging since readers will see both numbers. The divergence traces to the consolidation of Celliimune Biotech (acquired April 2026) and another unreviewed subsidiary that posted a ₹4.51 Cr net loss this quarter, plus a ₹0.66 Cr loss from the Concord Biotech Japan JV (versus a ₹1.28 Cr profit in Q1). None of these entities contribute meaningfully to revenue yet, so they show up as pure drag on consolidated profitability. Separately, Unit II cleared its USFDA inspection with only a minor observation (Sep 18, 2026) — a clean regulatory outcome that supports the export-led growth narrative from Q1 — and the board's 1:1 bonus issue (approved Sep 23) has its record date fixed for Nov 4, 2026, so the current quarter's EPS of ₹6.65 is still on the pre-bonus share base. Going into H2 FY27, the quarter sets up two things to track: whether the subsidiary-level losses narrow as Celliimune and the newer units mature, and whether OPM continues its sequential climb back toward the 35%+ territory of a year ago en route to the 40%-by-FY28 target.